Shares of Impax Laboratories, Inc. (NASDAQ:IPXL) have been given a consensus rating of “Hold” by the eighteen brokerages that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $18.54.

A number of analysts have recently weighed in on IPXL shares. Deutsche Bank AG set a $21.00 price objective on shares of Impax Laboratories and gave the stock a “buy” rating in a research note on Monday, July 17th. Cantor Fitzgerald increased their price objective on shares of Impax Laboratories from $20.00 to $25.00 and gave the stock an “overweight” rating in a research note on Monday, September 11th. BMO Capital Markets reiterated a “hold” rating and issued a $16.00 price objective on shares of Impax Laboratories in a research note on Friday, June 23rd. Zacks Investment Research lowered shares of Impax Laboratories from a “hold” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, Royal Bank Of Canada set a $17.00 price target on shares of Impax Laboratories and gave the stock a “hold” rating in a report on Thursday, August 10th.

Shares of Impax Laboratories (IPXL) traded down 3.48% during midday trading on Friday, reaching $20.80. 1,702,183 shares of the company traded hands. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $27.29. The company has a 50 day moving average price of $19.04 and a 200 day moving average price of $15.40. The company’s market capitalization is $1.49 billion.

Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The business had revenue of $202.08 million for the quarter, compared to analyst estimates of $195.62 million. During the same quarter in the prior year, the business posted $0.21 EPS. Impax Laboratories’s revenue for the quarter was up 17.1% compared to the same quarter last year. On average, analysts expect that Impax Laboratories will post $0.70 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/09/16/impax-laboratories-inc-ipxl-receives-average-rating-of-hold-from-analysts.html.

A number of institutional investors have recently added to or reduced their stakes in IPXL. State of Alaska Department of Revenue increased its position in Impax Laboratories by 1.9% during the first quarter. State of Alaska Department of Revenue now owns 8,140 shares of the specialty pharmaceutical company’s stock worth $102,000 after purchasing an additional 150 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in Impax Laboratories by 12.7% during the second quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock worth $111,000 after purchasing an additional 780 shares during the last quarter. Commerce Bank increased its position in Impax Laboratories by 12.9% during the first quarter. Commerce Bank now owns 11,460 shares of the specialty pharmaceutical company’s stock worth $145,000 after purchasing an additional 1,310 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Impax Laboratories by 1.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 14,414 shares of the specialty pharmaceutical company’s stock worth $182,000 after purchasing an additional 171 shares during the last quarter. Finally, Laurion Capital Management LP acquired a new stake in Impax Laboratories during the first quarter worth about $183,000. Hedge funds and other institutional investors own 86.26% of the company’s stock.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.